ES3054693T3 - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Info

Publication number
ES3054693T3
ES3054693T3 ES17881161T ES17881161T ES3054693T3 ES 3054693 T3 ES3054693 T3 ES 3054693T3 ES 17881161 T ES17881161 T ES 17881161T ES 17881161 T ES17881161 T ES 17881161T ES 3054693 T3 ES3054693 T3 ES 3054693T3
Authority
ES
Spain
Prior art keywords
bipolar disorder
mania
pharmaceutical composition
compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17881161T
Other languages
English (en)
Spanish (es)
Inventor
Yu Jin Shin
Sei Myoung Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES3054693T3 publication Critical patent/ES3054693T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17881161T 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder Active ES3054693T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
ES3054693T3 true ES3054693T3 (en) 2026-02-05

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17881161T Active ES3054693T3 (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
HUP0303261A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
BRPI0924997B1 (pt) 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
RU2019121913A (ru) 2021-01-15
JP2020502106A (ja) 2020-01-23
ZA201903747B (en) 2021-01-27
WO2018111008A1 (ko) 2018-06-21
KR102635938B1 (ko) 2024-02-13
CL2019001618A1 (es) 2019-08-23
AU2017374458B2 (en) 2023-03-02
US11571410B2 (en) 2023-02-07
RU2019121913A3 (enExample) 2021-04-21
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
IL267195A (enExample) 2019-07-31
KR20190087572A (ko) 2019-07-24
CA3046297A1 (en) 2018-06-21
BR112019011930A2 (pt) 2019-10-29
EP3556366B1 (en) 2025-10-22
CN110290788A (zh) 2019-09-27
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
MY199104A (en) 2023-10-13
MX2019006940A (es) 2019-09-06
AU2017374458A1 (en) 2019-07-04
JP7208139B2 (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
EP3556366B1 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP6986521B2 (ja) 頭痛の予防的治療のためのカルバメート化合物の使用
JP6960415B2 (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
ES2875058T3 (es) Uso de compuestos de fenoxipropilamina para tratar la depresión
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
ES2982316T3 (es) Uso de un compuesto de carbamato para prevenir, aliviar o tratar las crisis de ausencia o la epilepsia que muestra crisis de ausencia
ES2836685T3 (es) Agente para aliviar la hiperactividad del detrusor con deterioro de la contractilidad
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
ES2978226T3 (es) Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
ES2359910T3 (es) Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP4366533B2 (ja) 睡眠障害の治療剤
ES2973111T3 (es) Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
WO2007148950A1 (es) Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
BR112018073556B1 (pt) Uso de um composto de carbamato
TH98869A (th) การบำบัดโดยใช้ยาร่วมกันกับ 5-htp